Andrea Gombos

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

Journal: Breast cancer research and treatment

Published: February 28, 2026

ALFAssay: A feed‑forward neural network for quantitative fragmentomics‑based ctDNA profiling in breast cancer.

ALFAssay: A feed‑forward neural network for quantitative fragmentomics‑based ctDNA profiling in breast cancer.

Journal: PLoS computational biology

Published: February 13, 2026

Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.

Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 22, 2026

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 22, 2026

Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial.

Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 09, 2025

Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).

Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 05, 2025

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Journal: Nature medicine

Published: March 12, 2025

Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.

Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 14, 2025

Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.

Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 28, 2025

Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy.

Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 29, 2024

Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.

Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.

Journal: Journal for immunotherapy of cancer

Published: December 27, 2023

First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.

First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.

Journal: Journal for immunotherapy of cancer

Published: October 20, 2023

Showing 1-12 of 51

Last Updated: 09/26/2026